177Lu-PSMA

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug Name177Lu-PSMA
Drug Alias Name177Lu-PSMA
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)Radiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agent +[4] 
Mechanisms of ActionPositron-emission tomography enhancersIonising radiation emittersProstate-Specific Membrane Antigen inhibitors
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsNeoplasm MetastasisProstatic NeoplasmsCarcinoma, Renal Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPolandItalyFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIstituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori
China Registration ClassN/A

Develop Information

Active CompaniesCanadian Institutes Of Health Research (Cihr)Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST SRLMaria Sklodowska-Curie National Research Institute of Oncology +[4] 
Inactive CompaniesN/A
Active IndicationsNeoplasm MetastasisProstatic NeoplasmsCarcinoma, Renal Cell
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A